Michael Barbella, Managing Editor08.12.22
NanoVibronix Inc. is taking steps to fix medtech's long-broken supply chain.
The company announced it is shifting the majority of its manufacturing operations to Singapore to allow scalability, increase efficiency, and address potential supply chain delays.
“Plans are well underway to shift the majority of our third-party manufacturing to the industrial hub of Singapore,” stated Brian Murphy, CEO of NanoVibronix Inc. “Building a resilient supply chain is a top priority for us given the backlog of orders that we have to fill and the demand we see for our products. The transition, which we expect to be completed in the next few months, should enable us to scale while maintaining an equivalent cost and reducing our exposure to persistent geopolitical instability. Shifting to Singapore regionalizes our manufacturing and should enable us to meet regulatory compliance requirements. By streamlining the overall management of our supply chain, we are effectively addressing the related challenges we faced in the first half of 2022.”
“We remain optimistic about the growth prospects for our devices and are taking advantage of opportunities to be innovative with our processes to deliver product in a more expedient and cost-effective manner. We expect the full effects of this move to gain traction as we approach the end of 2022 and head into 2023. This move will address certain operational bottlenecks which have affected our ability to satisfy demand in a timely manner and scale up production,” Murphy added.
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with research and development in Nesher, Israel, focused on developing products utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.
The company announced it is shifting the majority of its manufacturing operations to Singapore to allow scalability, increase efficiency, and address potential supply chain delays.
“Plans are well underway to shift the majority of our third-party manufacturing to the industrial hub of Singapore,” stated Brian Murphy, CEO of NanoVibronix Inc. “Building a resilient supply chain is a top priority for us given the backlog of orders that we have to fill and the demand we see for our products. The transition, which we expect to be completed in the next few months, should enable us to scale while maintaining an equivalent cost and reducing our exposure to persistent geopolitical instability. Shifting to Singapore regionalizes our manufacturing and should enable us to meet regulatory compliance requirements. By streamlining the overall management of our supply chain, we are effectively addressing the related challenges we faced in the first half of 2022.”
“We remain optimistic about the growth prospects for our devices and are taking advantage of opportunities to be innovative with our processes to deliver product in a more expedient and cost-effective manner. We expect the full effects of this move to gain traction as we approach the end of 2022 and head into 2023. This move will address certain operational bottlenecks which have affected our ability to satisfy demand in a timely manner and scale up production,” Murphy added.
NanoVibronix Inc. is a medical device company headquartered in Elmsford, N.Y., with research and development in Nesher, Israel, focused on developing products utilizing its patented low intensity surface acoustic wave (SAW) technology. The proprietary technology allows for the creation of low-frequency ultrasound waves that can be utilized for a variety of medical applications, including for disruption of biofilms and bacterial colonization, as well as for pain relief. The devices can be administered at home without the assistance of medical professionals. The company’s primary products include PainShield and UroShield, which are portable devices suitable for administration at home without assistance of medical professionals.